Metamorphosis-Tx

Metamorphosis Tx, established on December 20, 2023, operates as a subsidiary of DCDC Tx with BioDetection Systems (BDS) as a co-founder. The entity is dedicated to advancing cancer treatment through the development of differentiation therapies.

Its approach leverages two proprietary technologies. DCDC Tx contributes its STAP STP technology, a software-based system with AI capabilities for measuring the activity of Signal Transduction Pathways in any cell or tissue sample, providing a detailed understanding of cellular differentiation. Complementing this, BDS provides its CALUX STP technology, utilizing Chemical Activated Luciferase gene expression for high-throughput compound screening, toxicology, and ADME studies.

The combined application of STAP and CALUX technologies positions Metamorphosis Tx to pursue new drug discovery and the repurposing of existing drugs. This dual strategy aims to accelerate the development of cancer differentiation therapies. The core technological capability allows for steering and monitoring cancer cell differentiation, utilizing cancer models, and advancing precision treatment methodologies.

Metamorphosis Tx focuses on the oncology market, specifically targeting the research and development of novel cancer treatments. Its activities suggest a business model centered on creating valuable intellectual property, with potential revenue from licensing developed therapies or forming strategic partnerships for further clinical development and commercialization. The STAP STP technology was developed, validated, and patented within Phi None.

Keywords: Cancer Differentiation Therapy, STAP STP Technology, CALUX Technology, Drug Discovery, Drug Repurposing, Signal Transduction Pathways, Precision Oncology, Biotechnology, Pharmaceutical R&D, Cellular Analysis